Real world use of loteprednol etabonate ophthalmic gel 0.5% in cases representative of comorbid pathologies responding to minimally invasive glaucoma surgery
JD Sheppard,1 IP Singh21Department of Ophthalmology, Eastern Virginia Medical School, Norfolk, VA, USA; 2Department of Glaucoma, The Eye Centers of Racine & Kenosha, Racine, WI, USAPurpose: With the increasing use of minimally invasive surgical techniques for intraocular pressure (IOP) lower...
Main Authors: | Sheppard JD, Singh IP |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-07-01
|
Series: | Clinical Ophthalmology |
Subjects: | |
Online Access: | https://www.dovepress.com/real-world-use-of-loteprednol-etabonate-ophthalmic-gel-05-in-cases-rep-peer-reviewed-article-OPTH |
Similar Items
-
A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty
by: Khaimi MA
Published: (2018-02-01) -
A Comparative Study of Efficacy and Safety of Topical Loteprednol Etabonate 0.5% and Cyclosporin A 0.05% for the Treatment of Vernal Keratoconjunctivitis
by: Sharika Ganjoo, et al.
Published: (2020-12-01) -
Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies
by: Fong R, et al.
Published: (2019-08-01) -
Cytarabine-Induced Corneal Toxicity: Clinical Features and Relief of Symptoms with Loteprednol Etabonate 0.5% in Two Patients
by: Gökçen Özcan, et al.
Published: (2021-04-01) -
Practical Guidance for the Use of Loteprednol Etabonate Ophthalmic Suspension 0.25% in the Management of Dry Eye Disease
by: Bian, Y., et al.
Published: (2022)